Skip to main content

Table 4 Overall survival, 7-gene signature, and Kaplan–Meier estimates

From: A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD)

Variables

Groups

Training group

Low risk (n = 51)

High risk (n = 51)

Deaths—no. (%)a

2

15

Data censoredb

49

36

Median overall survival—mo (95% CI)

NE

NE

The overall survival (95% CI) by Kaplan–Meier estimation

 3.60 mo

NA

98 (94.3–1)

 10.70 mo

NA

90.2 (82.4–98.7)

 13 mo

98 (94.2–1)

84.3 (74.9–94.9)

 23.57 mo

NA

82.3 (72.5–93.5)

 27 mo

96 (90.7–1)

76.2 (65.3–88.9)

 31 mo

NA

73.9 (62.6–87.2)

 31.5 mo

NA

68.6 (56.4–83.5)

Validation group (TCGA data)

Low risk (n = 261)

High risk (n = 261)

Deaths—no. (%)a

62

125

Data censoredb

199

136

Median overall survival—mo (95% CI)

77.3 (55.1–NE)

36 (31.6–42.2)

The overall survival (95% CI) by Kaplan–Meier estimation

36–39.8 mo

75.4 (68.77–82.7)

49.9 (42.95–58.1)

77–79 mo

48.7 (38.29–61.8)

25.1 (17.72–35.6)

106–112 mo

42.6 (29.85–60.7)

15.2 (8.21–28.2)

  1. NA indicate that there is no available events
  2. NE represent that the value could not be estimated
  3. aRepresent the hazard ratio for death
  4. bIndicate the date for censorship of patients on the date the patient was last known to be alive